Loading
BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 6 cohorts (4 activating, 2 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner.
No product in this corpus aims at BTG2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA BTG2: RNA low tissue specificity; no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P78543; CIViC gene BTG2; IntOGen BTG2; Human Protein Atlas BTG2 tissue; Open Targets ENSG00000159388 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Rouault J.-P. et al, Nat. Genet, 1996, "Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway". Source.
Sources: HGNC HGNC:1131 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P78543 (protein name, function text, keywords and locations (REST API)); CIViC gene BTG2 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen BTG2 (driver in 6 cohorts (Act 4, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors. Modulates transcription regulation mediated by ESR1. Locus 1q32.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer stained high; medium in breast cancer, carcinoid, glioma, prostate cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BTG2" OR ABSTRACT:"BTG2" OR TITLE:"BTG anti-proliferation factor 2" OR ABSTRACT:"BTG anti-proliferation factor 2" OR TITLE:"PC3" OR ABSTRACT:"PC3" OR TITLE:"TIS21" OR ABSTRACT:"TIS21" OR TITLE:"MGC126063" OR ABSTRACT:"MGC126063" OR TITLE:"MGC126064" OR ABSTRACT:"MGC126064") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BTG2, not a curated reading list.